- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00510380
Epigenetic Markers in Growth Restricted Human Pregnancies: a Case-controlled Study
Epigenetic Markets in Growth Restricted Human Pregnancies: A Case- Control Study
This study is carried out to discover if a baby with restricted growth in the womb is subject to specific fetal programming which predisposes to the metabolic syndrome(diabetes,hypertension,heart disease) in adulthood.We have elected to first study this condition in Chinese population in Singapore with the eventual plan of studying all ethnic groups. This is important for understanding the molecular basis of adult-onset disease such as diabetes, identifying children at risk of developing this disease in future and targeting specific strategies for intervention and disease prevention.
Intrauterine fetal programming is effected through epigenetic changes similar to those previously identified in animal studies. The epigenetic markers can be found in growth restricted Chinese pregnancies in the local population.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Fetal growth restriction is associated with accelerated postnatal weight gain and increased obesity risk in later life.International epidemiological data suggest that the phenomenon of fetal programming links poor intrauterine growth to adult disease, primarily type II diabetes, obesity and metabolic syndrome, conditions increasingly common in Singapore. Suboptimal intrauterine environmental condition s are postulated to affect fetal development through effects on developmental plasticity through epigenetic processes. These effects manifest as poor glucose resistance, insulin resistance, obesity and cardiovascular disease in later life. There is increasing animal data to support this model.
The aim of this study is to determine if epigenetic markers of the metabolic syndrome are present in selected Chinese pregnancies in Singapore.
Hypothesis:
Intrauterine fetal programming is effected through epigenetic changes similar to those previously identified in animal studies. The epigenetic markers can be found in growth restricted Chinese pregnancies in the local population.
Methodology Umbilical cords and cord blood will be collected from twenty unequivocally growth-restricted Chinese pregnancies and twenty appropriately-grown Chinese pregnancies. DNA extracted from these tissues will be subjected to a custom-made DNA methylation array probing for specific changes in 262 candidate genes important to fetal endocrine and metabolic control.
This will be done using either a methylation array or a Sequenorn 2 in the DNA extracts that have been identified through Epigen academic consortium of the Liggins Institute and UK collaborators.
Anthropometric data will be collected from the infants at birth, and subsequently at 3,6,12,18 and 24 months and we will seek differential measures of programming.
Application The discovery of biomarkers indicating shifted developmental trajectories is the most important need in developmental programming research. Birth weight alone is not a valid measure. Biomarkers predictive of later obesity and the metabolic syndrome will be invaluable in formulating preventive strategies for these diseases.
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienorte
-
-
-
Singapore, Singapur, 119074
- National University Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Chinese women,
- Singleton pregnancies,
- fetal growth restriction diagnosed clinically and by ultrasound parameters,
- Normally grown fetuses by clinical and ultrasound criteria
Exclusion Criteria:
- Non-Chinese women
- Multiple pregnancies
- Co-existing antenatal complications including sever pre-eclampsia
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
growth-restricted Chinese pregnancies
|
|
appropriately-grown Chinese pregnancies
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Yap Seng Chong, MBBS, National University Hospital, Singapore
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- SIG/07072
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Fötale Wachstumsverzögerung
-
Alzahraa Ismail Ragheb GodaUnbekanntGeburt, Komplikationen, mütterlicherseits | Geburt, Komplikation, FetalÄgypten
-
Queen Savang Vadhana Memorial Hospital, ThailandAbgeschlossen
-
University College CorkCork University HospitalAbgeschlossenFrühgeburt des Neugeborenen | Unterernährung; Intrauterin oder fetal, klein für Datteln
-
Weill Medical College of Cornell UniversityBeendetFieber | Herzfrequenz, fetal (FHR)Vereinigte Staaten
-
Taipei Veterans General Hospital, TaiwanNational Yang Ming UniversityUnbekanntEpithelial Growth Factor Receptor Negativer nicht-kleinzelliger Lungenkrebs
-
Hillel Yaffe Medical CenterAbgeschlossenFetal-mütterliche BlutungIsrael
-
Washington University School of MedicineAbgeschlossenFötale Hypoxie | Elektronische fetale Überwachung | Fetal-plazentarer KreislaufVereinigte Staaten
-
One Heart WorldwideRekrutierungMutter-fötale Beziehungen | Postpartale Blutung | Erstickung; FetalNepal
-
Ankara City Hospital BilkentUnbekanntSchwangerschaft bezogen | Fetal; Verkehr
-
Shanghai Junshi Bioscience Co., Ltd.Noch keine RekrutierungLokal fortgeschrittenes, metastasiertes oder rezidivierendes nicht-kleinzelliges Lungenkarzinom (NSCLC) mit Epidermal-Growth-Factor-Rezeptor (EGFR)-MutationenChina